Drug Database · Clinicians

Sodium bicarbonate

Brands (45) Bicarnate, Bicarbisaph, Bicargen…Show all

Antacid; Electrolyte Replenisher/Systemic alkalinising agent; and others PH FDA category

Sodium load: watch fluid, BPRx · Prescription drugOTC · Over-the-counterHR · Household remedy68 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Household remedy (HR) · Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b50c858a-00c8-4cb2-ad73-8797f19e656d, version date August 14, 2026 (sodium bicarbonate · Baxter Healthcare Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis.
  • to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Sodium bicarbonate injection is an alkalinizing agent indicated:

  • to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. (1.1)
  • to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. (1.2) Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution. 1.1 Treatment of Clinically Significant Metabolic Acidosis Sodium bicarbonate injection is indicated to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. 1.2 Urinary Alkalization in Drug Poisoning Sodium bicarbonate injection is indicated to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution.

Contraindications

  • Chloride loss from vomiting or continuous gastrointestinal suction
  • Diuretics that cause hypochloremic alkalosis
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (4)

Dosing: Adult

  • Metabolic acidosis (IV, adults): 2 to 5 mEq/kg over 4 to 8 hours, guided by blood gases and clinical state
  • CKD metabolic acidosis (oral tablets; KDIGO 2024): Consider treatment to keep serum bicarbonate from falling below 18 mmol/L, without exceeding the upper limit of normal; 650 mg tablet ≈ 7.7 mEq, 325 mg ≈ 3.9 mEq. No oral dose in the US label.
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Sodium bicarbonate injection is administered by intravenous infusion. (2.1)
  • Do NOT dilute prior to administration. (2.1)
  • Recommended Dosage in Adults and Pediatric Patients 2 Years of Age and Older Administer 2 mEq/kg to 5 mEq/kg of sodium bicarbonate injection over a four-to eight-hour period, depending upon the severity of metabolic acidosis as assessed by serum bicarbonate concentration, total CO 2, blood pH and the clinical condition of the patient. (2.2)
  • Recommended Dosage in Pediatric Patients Less Than 2 Years of Age, including Neonates Administer 1 mEq/kg to 2 mEq/kg of sodium bicarbonate injection over a four-to eight-hour period. Avoid rapid or bolus administration. (2.2)
2.1 General Administration Instructions

2.1 General Administration Instructions Inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy or if it contains particulate matter. Discard any unused portion. Sodium bicarbonate injection is a ready to administer product that requires no further dilution prior to infusion.

Administer sodium bicarbonate injection by intravenous infusion, via a dedicated line. Individualize dosage depending on the severity of the acidosis. Treatment of metabolic acidosis with sodium bicarbonate should be superimposed on measures designed to address the underlying cause of metabolic acidosis.

2.2 Recommended Dosage

2.2 Recommended Dosage Recommended Dosage in Adults and Pediatric Patients 2 Years of Age and Older Administer 2 mEq/kg to 5 mEq/kg of sodium bicarbonate injection over a four- to eight-hour period, depending upon the severity of metabolic acidosis as assessed by serum bicarbonate concentration, total CO 2, blood pH and the clinical condition of the patient. Recommended Dosage in Pediatric Patients Less Than 2 Years of Age, including Neonates Administer 1 mEq/kg to 2 mEq/kg of sodium bicarbonate injection over a four- to eight-hour period.

Avoid rapid or bolus administration [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

Dosing: Altered kidney function

Sodium bicarbonate is an alkalinizing agent; the bicarbonate is handled by the kidney and lungs, so there is no kidney dose reduction. The kidney concern is the sodium load: the US label (isotonic IV solution) asks for monitoring for fluid overload in kidney disease and anuria, plus electrolytes to avoid alkalosis and hypernatremia. Oral tablets used for the metabolic acidosis of CKD are outside this label; KDIGO 2024 suggests considering treatment when serum bicarbonate is below 18 mmol/L, without overshooting the upper limit of normal.

Kidney function measure: Not applicable: dosing is by acid-base status, not kidney function.

Show full dosing details
CrCl ≥60 mL/min
IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
CrCl 30–59 mL/min
No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
CrCl 15–29 mL/min
No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
CrCl <15 mL/min (not on dialysis)
No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
Hemodialysis (intermittent)
No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
Peritoneal dialysis
No dose change; watch sodium load and fluid status (label 5.1).
CRRT
No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
  • Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
  • Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Dose by acid-base status (label).
eGFR 30–59
No dose change; watch sodium load and fluid status (label 5.1).
eGFR 15–29
No dose change; watch sodium load.
eGFR <15 (not on dialysis)
No dose change; watch sodium load.
Hemodialysis (intermittent)
No dose change; fluid overload risk (label 5.1).
Peritoneal dialysis
No dose change; watch sodium load.
CRRT
No data; specialist.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Dosing: Pediatric

Approved ages
All ages, including neonates (label).
Usual dose
2 years and older: 2 to 5 mEq/kg over 4 to 8 hours. Under 2 years and neonates: 1 to 2 mEq/kg over 4 to 8 hours; avoid rapid or bolus doses (label).
Maximum dose
Under 2 years: rate no more than 8 mEq/kg/day (label 8.4).
Neonates
1 to 2 mEq/kg over 4 to 8 hours; no more than 8 mEq/kg/day; rapid injection risks hypernatremia and intracranial hemorrhage (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Sodium bicarbonate injection is indicated in pediatric patients:

  • To raise plasma pH in pediatric patients with clinically significant metabolic acidosis
  • To alkalinize the urine in drug poisoning in cases in which urinary drug elimination is enhanced by urinary alkalinization Rapid injection of sodium bicarbonate injection solutions into neonates and children under two years of age may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible intracranial hemorrhage. The rate of administration in such patients should therefore be limited to no more than 8 mEq/kg/day.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of sodium bicarbonate injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Administration

2.1 General Administration Instructions Inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy or if it contains particulate matter. Discard any unused portion. Sodium bicarbonate injection is a ready to administer product that requires no further dilution prior to infusion. Administer sodium bicarbonate injection by intravenous infusion, via a dedicated line. Individualize dosage depending on the severity of the acidosis. Treatment of metabolic acidosis with sodium bicarbonate should be superimposed on measures designed to address the underlying cause of metabolic acidosis.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 50 mg/mL, 84 mg/mL
  • Tablet: 325 mg, 650 mg
  • Solution for iv injection: 84 mg/mL
  • Solution: 3 g/100 mL, 208.75 mg/5 mL
  • ) solution for infusion: 1 mEq/mL
  • ) solution for injection: 84 mg/mL
  • Film-coated tablet: 650 mg
  • Solution for intravenous infusion: 84 mg/mL
  • Solution for intravenous injection: 84 mg/mL

Registered products in the Philippines

68 products registered with the Food and Drug Administration (FDA) Philippines list Sodium bicarbonate as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Sodium Bicorbonate (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products68
Philippine FDA-registered products for Sodium bicarbonate
Package insert
AccenateSodium Bicarbonate
650 mg TabletAmber Glass Bottle x 100's (Box of 1's)
OTC
Opal Laboratories (Pvt.) Limited.Pakistan
Accesspoint International Trading Inc.
DRP-17457
Dec 19, 2030
AcidNormSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Marcburg Philippines, Inc.Importer: JLT Pharma, Inc.
DRP-10801-02
Dec 21, 2031
AenabiSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's) and 20 mL ( Box of 50's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Dynasty PharmaceuticalsImporter: PhilRx Pharma Inc.
DRP-12551-02
Sep 9, 2027
AlkarbSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (IV)USP type I white ampoule x 10 mL (Box of 5's)
Rx
Unijules Life Sciences LimitedIndia
Aglobal Care, Inc.
DRP-15405
Jul 2, 2029
Balsamo CarminativoSodium Bicarbonate
208.75 mg/5 mL SolutionClear Plastic bottle x 15 mL; Clear Plastic bottle x 30 mL; Clear Plastic bottle x 60 mL; Clear Plastic bottle x 120 mL
HR
Ace Pharmaceuticals, Inc.Philippines
—
HRP-350
May 7, 2028
Bicarbillen-PE84Sodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (IV Infusion)10 mL and 20 mL USP Type I clear glass ampoule (Box of 50’s)
Rx
Penam Biosciences Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-18593
Aug 4, 2031
BicarbisaphSodium Bicarbonate
650 mg TabletAmber Glass Bottle with ROPP Cap x 100's (Box of 100's)
OTC
Sapphire Lifesciences Pvt. Ltd.India
Ollen Pharma Trading Inc.Trader: Shree Sainath International
DRP-13895
May 12, 2028
BicarbisaphSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 10 mL and 20 mL (net content) in PVC Plastic Tray (Box of 50's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences Inc.
DRP-11307
Nov 23, 2026
BicarbolenSodium Bicarbonate
325 mg TabletAmber glass bottle x 100's with ROPP cap (Box of 1's)
OTC
Sapphire Lifesciences Pvt., Ltd.India
Ollen Pharma Trading Inc.
HRP-635
Nov 24, 2028
Bicarbollen-B84Sodium Bicarbonate
84mg/mL (8.4 w/v) Solution For Injection (IV Infusion)Type I Clear Glass Ampoule x 10 mL and 20 mL (Box of 50's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-18973
Oct 8, 2031
BicarbozenSodium Bicarbonate
650 mg TabletHDPE Plastic Bottle x 30's, 60's, and 100's with HDPE Screw Cap
OTC
Azarias Pharmaceutical Laboratories, Inc.Philippines
Kodapharm Med Corp.
DRP-9492-04
Jan 25, 2031
BicardikonSodium Bicarbonate
84 mg/mL (8.4% w/v)Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
Pharmakon Pharmaceutical Inc.Importer: H & B Pharma International Inc.
DRP-12382--03
Jul 29, 2027
BicardoneSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50's)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: JLT Pharma Inc.
DRP-10801-06
Dec 21, 2026
BicargenSodium Bicarbonate
325 mg TabletHDPE Plastic Bottle with HDPE Screw Cap x 30's, 60's and 100's
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-9212
Nov 25, 2030
BicargenSodium Bicarbonate
650 mg TabletHDPE Plastic Bottle with HDPE Screw Cap x 60's N/A
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Trader: Eba Generisch Trading Inc.
DRP-9213
Nov 25, 2030
BicarlifeSodium Bicarbonate
650 mg TabletAlu-Dark Maroon PVC (Box of 100's)
OTC
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17625
Feb 10, 2031
BicarnateSodium Bicarbonate
325 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories, Inc.Philippines
—
DRP-14829
Jan 17, 2029
BicarnateSodium Bicarbonate
325 mg TabletHDPE Plastic Bottle x 30's, 60's and 100's with HDPE Screw Cap
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-9493
Jan 25, 2031
BicarnateSodium Bicarbonate
650 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's)
OTC
Azarias Pharmaceutical Laboratories, Inc.Philippines
—
DRP-14828
Jan 17, 2029
BicarnateSodium Bicarbonate
650 mg TabletHDPE Plastic Bottle x 30's, 60's, and 100's with HDPE Screw Cap
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-9492
Jan 25, 2031
BicarsaphSodium Bicarbonate
325 mg TabletAlu/Dark Maroon PVC Blister Pack x 10’s (Box of 100’s)
HR
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
HR-P577
Oct 19, 2031
BicarsaphSodium BicorbonateVariant spelling
325 mg TabletAlu/Dark Maroon PVC Blister Pack x 10's (Box of 100's)
HR
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
HRP-577
Mar 13, 2028
BisolunateSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
Novapharma Healthcare Inc.Importer: H & B Pharma International Inc.
DRP-12382-07
Jul 29, 2027
BykarSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (IV)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.Importer: H & B Pharma International Inc.
DRP-12382-06
Jul 29, 2027
GodariseSodium Bicarbonate
84 mg/mL (8.4 % w/v) Solution for Injection ( I.V. Infusion )USP Type I Colorless Glass Ampoule x 10 ml and 20 ml (net content) in PVC Plastic Tray (Box of 50's)
Rx
Kilitch Drugs (India) Ltd.India
Go Healthcare Pharmaceutical DistributionImporter: Nelpa Lifesciences Inc.
DRP-11307-01
Nov 23, 2026
KarbonetSodium Bicarbonate
325 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap
OTC
Azarias Pharmaceutical Laboratories, Inc.Philippines
Konzept Convenience and Drugstore Corp.
DRP-9493-02
Jan 25, 2031
KarbonetSodium Bicarbonate
650 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap
OTC
Azarias Pharmaceutical Laboratories, Inc.Philippines
Konzept Convenience and Drugstore Corp.
DRP-9492-02
Jan 25, 2031
KonabiSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
Dynasty PharmaceuticalsImporter: H & B Pharma International Inc.
DRP-12382-04
Jul 29, 2027
KurbacidSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Kurtmed Medical Distribution Inc.Importer: JLT Pharma Inc.
DRP-10801-09
Dec 21, 2031
MaxnateSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's)
Rx
Maxitech Pharma (Pvt) LtdPakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-15650
Aug 14, 2029
NacozidSodium Bicarbonate
650 mg Film-Coated TabletHDPE BOTTLE x 60’s (BOX of 1's)
OTC
UNI MEDICOLABSIndia
Greencore Pharma Inc.
DRP-18578
Jul 30, 2031
NahcoSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc.
DRP-15650-01
Aug 14, 2029
NapracidSodium Bicarbonate
325mg TabletClear PVC Blister Pack x 10's (Box of 100's)
OTC
Drugmaker's Laboratories Inc.Philippines
—
DRP-12999
Nov 16, 2027
NapracidSodium Bicarbonate
650 mg TabletClear PVC Blister Pack x 10's (Box of 100's)
OTC
Drugmaker's Laboratories Inc.Philippines
—
DRP-13000
Nov 16, 2027
NeutrazSodium Bicarbonate
650 mg TabletHDPE Bottle x 100's (Box of 1's)
OTC
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17330
Nov 18, 2030
NoneSodium bicarbonate
325 mg TabletAmber Glass Bottle x 100's
OTC
Amherst Laboratories, Inc.Philippines
Trader: Philusa Corporation
DR-XY26820
Jun 26, 2028
NoneSodium Bicarbonate
325 mg TabletAmber Glass Bottle x 100's with Metal Screw Cap
OTC
Amherst Laboratories. Inc.Philippines
Trader: Ritemed Phils., Inc.
DRP-8073
Jan 15, 2029
NoneSodium Bicarbonate
650 mg tabletAmber Glass Bottle x 100 tablets
OTC
AMHERST LABORATORIES, INC.Philippines
Trader: PHILUSA CORPORATION
DR-5070
May 29, 2028
NoneSodium Bicarbonate
650 mg TabletAlu/Dark Maroon-Colored PVC Blister Pack x 10’s (Box of 100’s)
OTC
Sai Parenterals Ltd.India
Ollen Pharma Trading, Inc.Trader: N/A
DRP-13745
Jul 21, 2031
NoneSodium Bicarbonate
650 mg TabletAmber Glass Bottle x 100's with Metal Screw Cap
OTC
Amherst Laboratories. Inc.Philippines
Trader: Ritemed Phils., Inc.
DRP-8074
Jan 15, 2029
NoneSodium Bicarbonate
650 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Hale Medipoint Corp.
DRP-9492-03
Feb 10, 2032
NoneSodium Bicarbonate
8.4 % (1 mEq/mL) Solution for Infusion (IV)Type I Clear Colorless Glass Ampoule x 10 mL and 50 mL (Box of 50's)
Rx
Atlantic Laboratories Corporation Ltd.Thailand
Phil Pharmawealth, Inc.
DR-XY28703
Jun 12, 2028
NoneSodium Bicarbonate
8.4% Solution for IV InfusionClear Colorless USP Type I Glass Bottle sealed with EPDM Rubber Stopper
Rx
B. Braun Melsungen AGGermany
Importer: B. Braun Medical Supplies, Incorporated
DR-XY15571
Apr 18, 2031
NoneSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's); USP Type I colorless glass ampoule in PVC plastic tray x 20 mL (Box of 50's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.Importer: PhilRx Pharma Inc.
DRP-12551-01
Sep 9, 2027
NoneSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Reta DrugImporter: Accesspoint International Trading Inc
DRP-15650-03
Aug 14, 2029
QodicSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
Amediqo Phils., Inc.Importer: H & B Pharma International Inc.
DRP-12382-02
Jul 29, 2027
RcarbonateSodium Bicarbonate
650mg TabletHDPE Bottle x 60's with HDPE Screw Cap
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Trader: St. Raphael, The Archangel Pharmaceutical Distributor
DRP-12527
Aug 26, 2027
RobicarbSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Rx Global Sales and Mktg. Corp.Importer: JLT Pharma Inc.
DRP-10801-08
Dec 21, 2031
Royalenate®Sodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Intravenous InfusionUSP Type I Clear and colorless glass vial with bromobutyl rubber stopper and aluminum crimp seal and gray plastic cap x 20 mL (Box of 10's) and 50 mL (Box of 6's)
Rx
Royale Life Pharma Inc.Philippines
—
DRP-13257
Jan 19, 2028
RoybicarbSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear and colorless glass vial x 20 mL and ess glass vial x 20 mL and 50 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and yellow plastic cap (Box of 15's)
Rx
Royale Life Pharma Inc.Philippines
—
DRP-17010
Sep 5, 2030
Sobi-KSodium bicarbonate
84 mg / mL (8.4 w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Kurtmed Medical Distribution Inc.Importer: Accesspoint International Trading Inc.
DRP-15650-02
Aug 14, 2029
SobicardSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50's)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Ellebasy Medicale Group Inc.Importer: JLT Pharma, Inc.
DRP-10801-03
Dec 21, 2026
SobinateSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Greencore Pharma Inc.Importer: JLT Pharma Inc.
DRP-10801
Dec 21, 2031
SobirlifeSodium Bicarbonate
325 mg TabletAlu-Dark Maroon PVC Blister Pack x 10's (Box of 100's)
OTC
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16565
Apr 29, 2030
SobitrisSodium Bicarbonate
50 mg/mL (5% w/v) Solution for Injection (IV)USP Type I Clear Glass Vial Ampoule x 1 mL and 2 mL (Box of 10's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17343
Nov 19, 2030
SodicarbSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's)
Rx
Jeil Pharmaceutical Co., Ltd.Republic of Korea
RCT Med Pharma CorporationImporter: H & B Pharma International Inc.
DRP-12382-05
Jul 29, 2027
SodiqoSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Amediqo Phils., Inc.Importer: JLT Pharma, Inc.
DRP-10801-04
Dec 21, 2031
SodrogenSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 10's and 50's); USP Type I colorless glass ampoule in PVC plastic tray x 20 mL (Box of 10's and 50’s)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Vintel Med EnterprisesImporter: PhilRx Pharma Inc.
DRP-12551-03
Sep 9, 2027
SodulaneSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Medlane Pharma Inc.Importer: JLT Pharma Inc.
DRP-10801-05
Dec 21, 2031
SolucentSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content). Box of 50's
Rx
BC WORLD Pharm. Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: JLT Pharma, Inc.
DRP-10801-01
Dec 21, 2026
SolunateSodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 20 mL (Box of 50's)
Rx
Dai Han Pharm. Co., Ltd.Korea
Endure Medical Inc.
DR-XY44425
Apr 16, 2031
UnbrandedSodium Bicarbonate (Balsamo Carminativo)
3 g/100 mL (3% w/v) SolutionWhite Translucent HDPE Bottle 30 mL; White Translucent HDPE Bottle 60 mL; White Translucent HDPE Bottle 120 mL
Rx
Maridan Industries, Inc.Philippines
—
DRHR-1976
Apr 6, 2031
UnicarbSodium bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection(I.V. Infusion)USP Type I Colorless Glass Ampoule x 20mL(net content) (Box of 50's)
Rx
BC World Pharm. Co., Ltd.Republic of Korea
Zen Pharma IncorporationImporter: JLT Pharma Inc.
DRP-10801-07
Dec 21, 2026
United Home Supracid Extra StrengthSodium Bicarbonate
650 mg TabletHDPE Bottle x 100's
HR
Unilab, Inc.Philippines
—
DRHR-539
Mar 7, 2037
(no brand name)Sodium Bicarbonate
8.4% (84 mg/mL) Solution for Injection (IV)Clear Vial x 50 mL (Box of 1's)
Rx
Hospira, Inc.U.S.A.
Pfizer, Inc
DR-XY6202
Jul 30, 2030
(no brand name)Sodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)Abboject Syringe (Calibrated USP Type I Glass Vial with Blue Butyl Rubber and Plastic Syringe Barrel) (Box of 1's)
Rx
Hospira, Inc.U.S.A.
Pfizer, Inc
DR-XY17168
Jul 16, 2030
(no brand name)Sodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's) and 20 mL (Box of 50's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-12551
Sep 9, 2027
(no brand name)Sodium Bicarbonate
84 mg/mL (8.4% w/v) Solution for Intravenous (IV) InjectionUSP Type I Clear Glass Ampoule x 10 mL (Box of 50's)
Rx
Aculife Healthcare Private LimitedIndia
Blue Global (FZE)
DRP-12825
Oct 11, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Sodium Bicarbonate Injection is a clear, colorless, sterile, nonpyrogenic, isotonic solution intended for intravenous use and available as: Injection: 12.6 mg/mL (0.150 mEq/mL), 12,600 mg of sodium bicarbonate injection in 1,000 mL single-dose Viaflo container Injection: 12.6 mg/mL (0.150 mEq/mL), 12,600 mg of Sodium Bicarbonate Injection in 1,000 mL single-dose Viaflo container. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Edema with Sodium Retention: Monitor patients who are sensitive to sodium intake (heart failure, hypertension, kidney disease, anuria, edema) for signs of fluid overload and adjust as appropriate. (5.1)
  • • Electrolyte Imbalances: Therapy with sodium bicarbonate injection can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Monitor electrolytes periodically during administration and treat abnormalities appropriately. Dosing with sodium bicarbonate injection results in a large volume of administration in younger and lighter weight pediatric patients. Consider use of more concentrated sodium bicarbonate formulations in these pediatric populations. (5.2)
  • • Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (5.3)
5.1 Edema with Sodium Retention

5.1 Edema with Sodium Retention Sodium bicarbonate injection can cause sodium retention and volume overload. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, kidney disease, anuria, edema) for signs of fluid overload and adjust sources of sodium as appropriate.

5.2 Electrolyte Imbalances

5.2 Electrolyte Imbalances Sodium bicarbonate injection may cause electrolyte imbalances. Overly aggressive therapy with sodium bicarbonate injection can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Monitor electrolytes periodically during administration and treat abnormalities appropriately.

Dosing with sodium bicarbonate injection results in a large volume of administration in younger and lighter weight pediatric patients. Consider use of more concentrated sodium bicarbonate formulations in these pediatric populations [see Dosing and Administration (2)].

5.3 Extravasation

5.3 Extravasation Inadvertent extravasation of intravenously administered hypertonic solutions of sodium bicarbonate have been reported to cause chemical cellulitis because of their alkalinity, with tissue necrosis, ulceration or sloughing at the site of infiltration. Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site of intravenous solution extravasation.

Drug interactions

Drug or classSeverityEffectWhat to do
Diuretics causing hypochloremic alkalosisAvoidWorsened alkalosis (label contraindication).Do not use together.
Other sodium sourcesAdjust or monitorAdditive sodium load (label 5.1).Adjust total sodium intake.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Edema from sodium retention
  • Electrolyte changes (hypernatremia, metabolic alkalosis, hypokalemia)
  • Extravasation (chemical cellulitis)

Serious

  • Fluid overload, heart failure
  • Severe metabolic alkalosis with tetany
  • Tissue necrosis after extravasation of hypertonic solution
  • Hypernatremia and intracranial hemorrhage after rapid injection in infants
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: • Edema with Sodium Retention [see Warnings and Precautions (5.1)] • Electrolyte Imbalances [see Warnings and Precautions (5.2)] • Extravasation [see Warnings and Precautions (5.3)] Adverse reactions include edema with sodium retention, electrolyte imbalances and extravasation. (6) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-877-725-2747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Monitoring parameters

  • Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions). Kidney
  • Bicarbonate or blood gases
  • Sodium and potassium
  • Fluid status and blood pressure
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from published literature over decades of use have not identified a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Physiological replacement of sodium bicarbonate is not expected to lead to increased risk of adverse fetal or maternal outcomes.

Animal reproduction studies have not been conducted with sodium bicarbonate. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Mechanism of action

12.1 Mechanism of Action Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH.

US FDA label

Pharmacokinetics

Key PK parameters

OnsetImmediate (IV)
Metabolism (CYP, transporters)Bicarbonate converted to carbon dioxide and water (lungs)
Renal excretion kidneyUnder 1% of filtered bicarbonate in urine at normal function; excess excreted by the kidney
Dialyzability kidneyCrosses dialysis membranes (physiology)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Bicarbonate anion is considered “labile” since at a proper concentration of hydrogen ion (H + ) it may be converted to carbonic acid (H 2 CO 3 ) and then to its volatile form, carbon dioxide (CO 2 ) excreted by the lung.

In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% is excreted in the urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution Sodium bicarbonate in water dissociates to provide sodium (Na +) and bicarbonate (HCO 3 -) ions. Sodium (Na +) is the principal cation of the extracellular fluid. Bicarbonate (HCO 3 -) is a normal constituent of body fluids. Elimination Plasma bicarbonate concentration is regulated by the kidney through acidification of the urine when there is a deficit or by alkalinization of the urine when there is an excess.

Bicarbonate anion is considered “labile” since at a proper concentration of hydrogen ion (H +) it may be converted to carbonic acid (H 2 CO 3) and then to its volatile form, carbon dioxide (CO 2) excreted by the lung. In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% is excreted in the urine.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Sodium Bicarbonate 1 mEq/ mL, 20 mL Ampule₱68.23–₱144.75Reference ₱68.23per ampuleDPRI procurement range
Sodium Bicarbonate 1 meq/mL, 50 mL Ampule₱90.68–₱119.99Reference ₱90.68per ampuleDPRI procurement range
Sodium Bicarbonate 1 meq/mL, 50 mL Vial₱90.00–₱110.00Reference ₱90.00per vialDPRI procurement range
Sodium Bicarbonate 650 mg Tablet₱0.99–₱5.25Reference ₱0.99per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Sodium Bicarbonate
PNF listingOral: 325 mg and 650 mg tablet
PNF listingInj.: 1 mEq/mL, 10 mL vial (pediatric), 20 mL, 50 mL and
PNF listingInj.: 100 mL ampul/vial (adult) (IV infusion)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. sodium bicarbonate · Baxter Healthcare Corporation [US FDA-approved label, version 1, August 14, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50c858a-00c8-4cb2-ad73-8797f19e656d
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Baxter Healthcare Corporation. (2026). Sodium bicarbonate injection 12.6 mg/mL (isotonic) [Prescribing information; US FDA-approved label, NDA218524, set ID b50c858a-00c8-4cb2-ad73-8797f19e656d, version effective August 14, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50c858a-00c8-4cb2-ad73-8797f19e656d
  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .